Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024

Chemomab Therapeutics Ltd.

2022-FY EPS reported $0.12

Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.
Cash used in operations was $20.4M; cash, equivalents and deposits fund operations through March 31, 2024.
Phase 2 PSC trial actively recruiting; added 20mg/kg dose arm and open-label extension.
Phase 2 SSc trial planned for H1 2023; completed NASH trial met safety endpoint with encouraging biomarker activity.
No revenue from product sales; accumulated deficit of $64M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Chemomab Therapeutics Ltd. reported financial results for fiscal year ended December 31, 2022.

Period: fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

Chemomab Therapeutics Ltd. (“we,” “us,” “our,” or the “Company”) is disclosing its consolidated audited financial statements for the fiscal year ended December 31, 2022

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-000670

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.